Navigation Links
Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
Date:8/6/2014

lus expects to report human proof-of-concept results in the Phase I clinical study of RG-101 for the treatment of HCV by the end of 2014, initiate a Phase I clinical study of RG-012 for the treatment of Alport syndrome in the first half of 2015, nominate a third microRNA candidate for clinical development by the end of 2014, and maintain a strong financial position and end 2014 with at least $75.0 million in cash, cash equivalents and short-term investments.

About RegulusRegulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company.
Regulus has a well-balanced microRNA therapeutics pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases.  Specifically, Regulus is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection.  Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec focused on microRNA biomark
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
2. Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
3. Regulus Announces Addition to NASDAQ Biotechnology Index
4. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
5. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
6. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
7. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
8. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
9. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
10. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
11. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food and ... for the prevention of serogroup B meningococcal disease ... Pfizer,s vaccine Trumenba®, which received FDA approval in October, ... devastating disease. "I have heard over ...
(Date:1/23/2015)... Iowa , Jan. 23, 2015  The Partnership to Fight Chronic ... health care leaders and a new study analyzing the ... The PFCD is a nationwide coalition working to educate policy makers ... released at the Capitol was focused on how the ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted living ... p.m. to 4 p.m. on Feb. 13. , The community, which ... with physical disabilities between the ages of 22 and 64. , ... sweetheart-themed karaoke. , For more information about the event or Deer ...
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Humans see color thanks to cone cells, specialized light-sensing neurons ... eyeball. The actual light-sensing section of these cells is called ... of stacked discs, each about 30 nanometers (billionths of a ... Scientists believe that a better understanding of how and why ...
... an associate professor of epidemiology at Boston University,s Slone ... grants from the National Institutes of Health. The first ... Environmental Health Sciences that will study air pollution and ... women. The second award is for a three-year study ...
... for Molecular Medicine (MDC) Berlin-Buch have found out why ... of the world,s most unusual mammals, feels no pain ... packed in narrow dark burrows where ambient carbon dioxide ... is converted into acid, which continuously activates pain sensors. ...
... "disarray and dysfunction" jeopardize access to medical care ... military families, said the American College of Physicians ... with House and Senate leadership. ACP is ... membership organizationin the United States, representing 132,000 internal ...
... early kidney injuries in people, doctors monitor blood level ... to understand the severity of the injury. Creatinine is ... indication of early damage to vital kidney function. For ... researchers have found that even tiny increases of creatinine ...
... MONDAY, Dec. 19 (HealthDay News) -- ,A new study finds ... one of the most aggressive forms of skin cancer. The ... Cutaneous melanoma is the fifth most commonly diagnosed cancer in ... U.S. women. Incidence of the cancer is increasing, and death ...
Cached Medicine News:Health News:Nanometer-scale growth of cone cells tracked in living human eye 2Health News:Boston University researcher awarded 2 NIH grants 2Health News:MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain 2Health News:MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain 3Health News:Congress' 'disarray' makes it 'likely' that 27 percent Medicare cut will go in effect 2Health News:MU researchers find pet kidney injuries are similar to human kidney injuries 2Health News:Previous Cancer May Up Melanoma Risk 2
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... disposable 1-ounce pouches are designed for individual ... They are used in nursing homes, home ... and many other hospital departments. This unit ... a mild antiseptic, germicidal and cleansing agent. ...
... a gentle and effective surgical scrub with ... Iodine is known to kill skin surface ... viruses, protozoa and yeasts. It produces a ... patient pre-operative prepping, as well as for ...
... is appropriate for pre-surgical patient preparation ... spray); disinfecting of wounds and burns; ... and abrasions. It also acts as ... and office procedures, providing protection against ...
Medicine Products: